The global bronchitis treatment market size is estimated to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the large patient control and increasing competitive activities of advancement of bronchitis treatment products.
Bronchitis refers to festering of the bronchial tubes that provide air to the lungs. Some other symptoms are wheezing, shortness of breath, low fever, and tight chest; among these cough with mucus is found to be a common condition of the patient suffering from the disorder. It is a respiratory disease where inflammation occurs of the bronchi within lungs.
The restraining elements that accelerate the chances of bronchitis are gastric reflux, cigarette smoking, and exposure to irritants during work such as chemicals, dust, and fumes. Additionally, it is most common that it usually occurs when the infection is becoming very intense into the lungs. This infection is the reason of air sacs in the lungs, which is filled with fluid.
The two types of bronchitis are acute bronchitis and chronic bronchitis. Acute bronchitis is a temporary condition of the disease infection in the lungs, which is also called as a chest cold. Most of the cases of acute bronchitis are caused by viruses and some of the most common symptom of acute bronchitis are fever, cough, wheezing, and shortness of breath. Meanwhile, chronic bronchitis, also known as chronic obstructive pulmonary disease, is a prolonged and long–term disease infection in the lungs. It is caused by airway tissue, damage to the lung and repeated irritation.
The report on the global bronchitis treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Bronchitis Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Treatments (Drugs and Oxygen Therapy), Drugs Class (Antibiotics, Anti-inflammatory Drugs, Bronchodilators, and Mucolytics), End-users (Hospitals, Clinics, and Drug Stores) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Boehringer Ingelheim; Dr. Reddy’s Laboratories Ltd; GlaxoSmithKline Pharmaceuticals Limited; Pfizer Inc.; and Sanofi Aventis. |
Based on treatments, the global bronchitis treatment market is bifurcated into oxygen therapy and drugs. The drugs segment accounted for a key share of the market in 2020 and is expected to grow at a rapid pace during the projected period due to advancement in the drug manufacturing technology. However, the oxygen therapy segment is anticipated to expand at a significant growth rate during the forecast period owing to increase in the adoption rate of the therapy for the particular disease treatment.
On the basis of drugs class, the market is divided into bronchodilators, anti-inflammatory drugs, bronchodilators, antibiotics, and mucolytics. The antibiotics segment is projected to expand at a considerable CAGR during the forecast period owing to low cost and easy availability of the drug type. Meanwhile, the mucolytics segment is anticipated to represent a healthy growth rate during the forecast period due to increasing demand for the drug among patients.
Based on end-users, the global bronchitis treatment market is segmented into drug stores, clinics, and hospitals. The hospitals segment held a dominant share of the market in 2019 and is expected to exhibit a robust growth rate in the coming years due to large number of increasing chronic diseases and frequent hospital visit by patients for the treatment. On the other hand, the clinics part is anticipated to hold a large market share during the projected period owing to rapid expansion of several clinics facilitating easy access at low cost.
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period due to increasing number of patients and rapid adoption of advanced treatment methods for various diseases in the region. The market of Asia Pacific, however, is expected to register a substantial growth rate in the coming years owing to increasing healthcare infrastructure and facilities under several governments’ initiatives in the region.
The global bronchitis treatment market has been segmented on the basis of
Key players competing in the global bronchitis treatment market are Boehringer Ingelheim; Dr. Reddy’s Laboratories Ltd; GlaxoSmithKline Pharmaceuticals Limited; Pfizer Inc.; and Sanofi Aventis. These main market players are continuously engaged in various business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to expand their business operations and widen their geographical reach.
The global bronchitis treatment market has been segmented on the basis of
Key players competing in the global bronchitis treatment market are Boehringer Ingelheim; Dr. Reddy’s Laboratories Ltd; GlaxoSmithKline Pharmaceuticals Limited; Pfizer Inc.; and Sanofi Aventis. These main market players are continuously engaged in various business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to expand their business operations and widen their geographical reach.
Some other reports from this category!